Second Revision of USP Chapter Injections and Implanted Drug Products (Parenterals)-Product Quality Tests

Posted on

After the revision of the General Chapter on quality testing of sterile medicinal products in the US American Pharmacopoeia had already been announced last year in the USP 38-NF 33, the USP is planning a new revision. Read more about the revision of Chapter <1>.

http://www.gmp-compliance.org/enews_05240_Second-Revision-of-USP-Chapter–1–Injections-and-Implanted-Drug-Products–Parenterals–Product-Quality-Tests_15090,15160,15266,Z-PEM_n.html

Last year already, the revision of the General Chapter on quality testing of sterile medicinal products was initiated in the USP 38 NF 33. The targeted official date for coming into force was the 1st May 2016. Now, the USP has announced that because of some comments received, there will be a further revision. This is due to the USP’s intention to support in Chapter 1 both existing monographs as well as new monographs to be developed. The new scope should now be focussed again to avoid confusion. The publication is striven for March 2016 as well as the adoption of the changes in the USP 40 NF 35. Furthermore, USP has announced that also the contents of General Chapters <2> to <5> will be examined.

On the USP website you will find further details regarding the revision of Chapter <1>.

///////USP 38-NF 33, revision of Chapter <1>, quality testing of sterile medicinal products, monographs, USP,  new revision

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s